Novartis (NVS) Grew Sales Again as Entresto Fell 50%, Can Remibrutinib Carry It?
Earlier this month, Novartis (NYSE:NVS) won a second US approval for Rhapsido, the drug also known as remibrutinib, this time for symptomatic dermographism, a form of chronic hives.







